CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 22.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 165,816 shares of the company’s stock after selling 48,278 shares during the period. Rafferty Asset Management LLC owned approximately 0.19% of CRISPR Therapeutics worth $6,527,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Intellectus Partners LLC lifted its stake in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the period. Farrow Financial Inc. lifted its stake in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after purchasing an additional 270 shares during the period. Kestra Private Wealth Services LLC lifted its stake in shares of CRISPR Therapeutics by 1.5% in the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after purchasing an additional 310 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of CRISPR Therapeutics by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock valued at $215,000 after purchasing an additional 372 shares during the period. Finally, Horizon Kinetics Asset Management LLC lifted its stake in shares of CRISPR Therapeutics by 4.3% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company’s stock valued at $420,000 after purchasing an additional 443 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Up 6.8%

CRISPR Therapeutics stock opened at $38.77 on Friday. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $67.88. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -8.87 and a beta of 1.88. The company has a fifty day simple moving average of $37.50 and a 200-day simple moving average of $42.36.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the previous year, the business posted ($1.43) EPS. CRISPR Therapeutics’s quarterly revenue was up 71.6% compared to the same quarter last year. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock valued at $1,608,243 over the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CRSP shares. Citigroup decreased their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $71.75.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.